DMDanielle N. Maryanski

Danielle N. Maryanski

*This is an algorithmically generated author record based on publicly available information.

Danielle N. Maryanski has a total of 147 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Biomarker-driven and gene-enhanced viral therapy for malignant peripheral nerve sheath tumor

    by Meghna Saxena, Love Li, Brady G. Strittmatter, Kyle Williams, Faruck L. Hakkim, Shraddha Potti, Alanna Halloran, Elsie Warren, Danielle Maryanski, Courtney Barnes, et al.

    Background: High-grade malignant peripheral nerve sheath tumors (MPNST) frequently lose Polycomb Repressive Complex 2 (PRC2), reducing the repressive histone mark, H3K27me3. We hypothesized that H3K27me3 loss sensitizes MPNST to oncolytic HSV due to impaired transcriptional resistance. HSV replication is also restricted by the integrated stress response, normally countered by HSV ICP34.5, representing an additional resistance pathway to ICP34.5 -attenuated HSV. Methods: PRC2 loss-of-function was evaluated as a biomarker of HSV G47Δ ( ΔICP34.5 ) susceptibility in MPNST using isogenic, pharmacologic inhibition, and genetic rescue models. CUT&RUN and RNA-sequencing defined PRC2-dependent viral and host responses. We engineered a G47Δ-derived vector (G47Δ 2 ) with tumor-regulated ICP34.5 expression [G47Δ 2 ,ins( BIRC5>ICP34.5 )] and evaluated efficacy in MPNST xenografts. Results: H3K27me3 deficiency increased G47Δ sensitivity and viral spread in vitro . CUT&RUN demonstrated PRC2-dependent H3K27me3 accumulation on the viral genome, explaining G47Δ activity in H3K27me3-deficient MPNST. RNA sequencing of G47Δ infected MPNST cells revealed heightened integrated stress response activity and blunted induction of translation-associated programs in the PRC2-deficient state (both p 2 (8.3%; 4.5–12.2%) and controls (22.5%; 17.4–27.8%). A murine gastrointestinal toxicity phenotype reduced all-cause event-free survival, indicating vector and dosing optimizations are needed to widen the therapeutic window. Conclusions: H3K27me3 loss creates a paradoxical antiviral state that tumor-selective ICP34.5 overcomes to rescue HSV anti-tumor activity, supporting biomarker-driven viral engineering to exploit the permissive transcriptional state of H3K27me3-deficient MPNSTs. Key Points: Loss of a key epigenetic mark (H3K27me3) MPNST is a biomarker of susceptibility to oncolytic HSV H3K27me3-deficient MPNST mounts a compensatory stress response that limits HSV propagation. Engineered viral gene therapy to overcome the stress response rescues antitumor activity. Importance of the Study: High-grade MPNST lacks effective systemic therapies, and biomarkers that can guide oncolytic virotherapy are poorly defined. This study identifies loss of PRC2-dependent H3K27me3 as a marker of susceptibility to oncolytic HSV but shows that this same epigenetic state also primes a compensatory integrated stress response that limits productive viral propagation at the level of protein translation. These findings connect a tumor-specific chromatin defect to both enhanced viral permissiveness and a compensatory resistance mechanism. By restoring tumor-selective expression of ICP34.5 , an HSV-encoded antagonist of the integrated stress response frequently removed to promote oncolytic vector attenuation, we demonstrate that this second barrier can be therapeutically targeted to improve antitumor activity. The work therefore provides a mechanistic framework for matching viral engineering to tumor epigenetic state. Robust anti-tumor activity must be balanced with therapeutic safety, providing avenues for further vector optimization. This biomarker-driven strategy may be relevant to other H3K27me3-deficient nervous system tumors.

  • Open Access

    Spatially-resolved single cell atlas of liposarcoma reveals lineage hierarchies, immune niches, and regulatory circuits

    by Ryan A. Denu, Veena Kochat, Zhao Zheng, Suresh Satpati, Danh D. Truong, Emre Arslan, Corey Weistuch, Margarita Divenko, Manrong Wu, William Padron, et al.

    Well-differentiated and dedifferentiated liposarcoma (WDLPS and DDLPS) exhibit markedly different clinical behaviors, with DDLPS showing greater aggressiveness, higher recurrence and metastasis rates, and worse outcomes. Using single-nucleus multiome sequencing, epigenomic profiling, and spatial transcriptomics, we characterized cellular and epigenetic heterogeneity between these subtypes at single-cell and spatial resolution. We found distinct phenotypic states reflecting altered lineage differentiation and plasticity: DDLPS is dominated by early-differentiated progenitor-like cells, sclerotic WDLPS displays broader mesenchymal lineage plasticity, and adipocytic WDLPS contains abundant committed adipocytes. The DDLPS immune microenvironment was dominated by immunosuppressive macrophages, whereas WDLPS harbored more T cells and inflammatory macrophages. Notably, sclerotic WDLPS displayed intermediate cellular and molecular features, suggesting it may represent a distinct WDLPS subtype. Importantly, we identified novel gene regulatory circuits underlying each state, including FABP4/PPARG programs in adipocytic WDLPS, GLI2/TCF7L2/RBPJ/KLF7 programs in sclerotic WDLPS, and KLF7/FOSL2/SP3/GLI2/RBPJ programs in DDLPS. H3K27ac-marked enhancers were enriched near adipocytic marker genes in WDLPS and mesenchymal markers in DDLPS. Together, these findings reveal the cellular heterogeneity of tumor and immune compartments across liposarcoma subtypes and identify regulatory programs driving their differentiation states. GRAPHICAL


  • NSD2 inhibitors rewire chromatin to treat lung and pancreatic cancers

    by Jinho Jeong, Simone Hausmann, Hanyang Dong, Kacper Szczepski, Natasha M. Flores, Andy Garcia Gonzalez, Liyang Shi, Xiaoyin Lu, Joanna Lempiäinen, Moritz Jakab, et al.

    NSD2 catalyses the epigenetic modification H3K36me2 (refs. 1,2) and is a candidate convergent downstream effector of oncogenic signalling in diverse malignancies3,4,5. However, it remains unclear whether the enzymatic activity of NSD2 is therapeutically targetable. Here we characterize a series of clinical-grade small-molecule catalytic NSD2 inhibitors (NSD2i) and show that the pharmacological targeting of NSD2 constitutes an epigenetic dependency with broad therapeutic efficacy in KRAS-driven preclinical cancer models. NSD2i inhibits NSD2 with single-digit nanomolar half-maximal inhibitory concentration potency and high selectivity over related methyltransferases. Structural analyses reveal that the specificity of NSD2i for NSD2 is due to competitive binding with S-adenosylmethionine and catalytic disruption through a binary-channel obstruction mechanism. Proteo-epigenomic and single-cell strategies in pancreatic and lung cancer models support a mechanism in which sustained NSD2i exposure reverses pathological H3K36me2-driven chromatin plasticity, re-establishing silencing at H3K27me3-legacy loci to curtail oncogenic gene expression programs. Accordingly, NSD2i impairs the viability of pancreatic and lung cancer cells and the growth of patient-derived xenograft tumours. Furthermore, NSD2i, which is well-tolerated in vivo, prolongs survival in advanced-stage autochthonous KRASG12C-driven pancreatic and lung tumours in mouse models to a comparable level as KRAS inhibition with sotorasib6. In these models, treatment with both a NSD2 inhibitor and sotorasib synergize to confer sustained survival with extensive tumour regression and elimination. Together, our work uncovers targeting of the NSD2–H3K36me2 axis as an actionable vulnerability in difficult to treat cancers and provides support for the evaluation of NSD2 and KRAS inhibitor combination therapies in a clinical setting.


  • Open Access

    Nucleosome context regulates chromatin reader preference

    by Matthew R. Marunde, Irina K. Popova, Nathan W. Hall, Anup Vaidya, James R. Bone, Brandon A. Boone, Peter J. Brown, Ryan J. Ezell, Tessa M. Firestone, Harrison A. Fuchs, et al.

    Chromatin is more than a simple genome packaging system, and instead locally distinguished by histone post-translational modifications (PTMs) that can directly change nucleosome structure and / or be “read” by chromatin-associated proteins to mediate downstream events. An accurate understanding of histone PTM binding preference is vital to explain normal function and pathogenesis, and has revealed multiple therapeutic opportunities. Such studies most often use histone peptides, even though these cannot represent the full regulatory potential of nucleosome context. Here we apply a range of complementary and easily adoptable biochemical and genomic approaches to interrogate fully defined peptide and nucleosome targets with a diversity of mono or multivalent chromatin readers. In the resulting data, nucleosome context consistently refined reader binding, and multivalent engagement was more often regulatory than simply additive. This included abrogating the binding of the Polycomb group L3MBTL1 MBT to histone tails with lower methyl states (me1 or me2 at H3K4, H3K9, H3K27, H3K36 or H4K20); and confirmation that the CBX7 chromodomain and AT-hook-like motif (CD-ATL) tandem act as a functional unit to confer specificity for H3K27me3. Further, in vitro nucleosome preferences were confirmed by in vivo reader-CUT&RUN genomic mapping. Such data confirms that more representative chromatin substrates provide greater insight to biological mechanism and its disorder in human disease.


  • Open Access

    High-efficiency genomic mapping of chromatin-associated targets with CUT&RUN

    by Tessa M. Firestone, Bryan J. Venters, Katherine Novitzky, Liz Marie Albertorio-Sáez, Courtney A. Barnes, Karlie N. Fedder-Semmes, Nathan W. Hall, Allison R. Hickman, Mark Kaderli, Carolina Lin Windham, et al.

    The precise regulation of chromatin composition is critical to gene expression and cellular identity, and thus a key component in development and disease. Robust assays to study chromatin features, including histone post-translational modifications (PTMs) and chromatin-associated proteins ( e.g. , transcription factors or PTM readers), are essential to understand their function and identify novel therapeutic strategies. To this end, Cleavage Under Targets and Release Using Nuclease (CUT&RUN) has emerged as a powerful tool for high-resolution epigenomic profiling. The approach has been successfully applied to numerous cell and tissue types, informing on target genomic distribution with unprecedented sensitivity and throughput. Here, we provide a detailed CUT&RUN protocol from sample collection through data analysis, including best practices and defined controls to ensure specific, efficient, and robust target profiling.


  • Open Access

    Cancer-associated DNA hypermethylation of Polycomb targets requires DNMT3A dual recognition of histone H2AK119 ubiquitination and the nucleosome acidic patch

    by Kristjan H. Gretarsson, Stephen Abini-Agbomson, Susan L. Gloor, Daniel N. Weinberg, Jamie L. McCuiston, Vishnu Udayakumar Sunitha Kumary, Allison R. Hickman, Varun Sahu, Rachel Lee, Xinjing Xu, et al.

    During tumor development, promoter CpG islands that are normally silenced by Polycomb repressive complexes (PRCs) become DNA-hypermethylated. The molecular mechanism by which de novo DNA methyltransferase(s) [DNMT(s)] catalyze CpG methylation at PRC-regulated regions remains unclear. Here, we report a cryo–electron microscopy structure of the DNMT3A long isoform (DNMT3A1) amino-terminal region in complex with a nucleosome carrying PRC1-mediated histone H2A lysine-119 monoubiquitination (H2AK119Ub). We identify regions within the DNMT3A1 amino terminus that bind H2AK119Ub and the nucleosome acidic patch. This bidentate interaction is required for effective DNMT3A1 engagement with H2AK119Ub-modified chromatin in cells. Further, aberrant redistribution of DNMT3A1 to Polycomb target genes recapitulates the cancer-associated DNA hypermethylation signature and inhibits their transcriptional activation during cell differentiation. This effect is rescued by disruption of the DNMT3A1–acidic patch interaction. Together, our analyses reveal a binding interface critical for mediating promoter CpG island DNA hypermethylation, a major molecular hallmark of cancer.